Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CK-101 |
| Synonyms | |
| Therapy Description |
CK-101 is a third generation EGFR inhibitor that preferentially binds to and inhibits mutant EGFR, particularly T790M, resulting in anti-tumor activity (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CK-101 | CK101|CK 101 | EGFR Inhibitor 3rd gen 28 | CK-101 is a third generation EGFR inhibitor that preferentially binds to and inhibits mutant EGFR, particularly T790M, resulting in anti-tumor activity (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02926768 | Phase Ib/II | CK-101 | Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors | Completed | USA | POL | NZL | AUS | 1 |